Table 2.
Tumour and laboratory variables at diagnosis
| Tumour and laboratory variables at diagnosis | |
|---|---|
| Tumour characteristics, n | |
| Single tumour | 25 |
| Multiple tumours | 21 |
| Size of the largest tumour, cm, median (range) | 4.4 (1–14) |
| Location of tumour, n | |
| Left lobe | 2 |
| Right lobe | 28 |
| Bilobar | 16 |
| Radiological vascular tumour invasion, n | |
| Present | 5 |
| Absent | 41 |
| TNM classification (AJCC, 7th Edition), n | |
| T1 | 9 |
| T2 | 15 |
| T3 | 22 |
| White blood cell count, ×109/l, median (range) | 5.9 (2.7–11.8) |
| Red blood cells, ×10120/l, median (range) | 4.0 (2.7–5.2) |
| Platelets, ×109/l, median (range) | 112 (49–462) |
| International normalized ratio, median (range) | 1.1 (1.0–2.4) |
| Potassium, mmol/l, median (range) | 4.1 (3.4–5.3) |
| Sodium, mmol/l, median (range) | 136 (127–143) |
| Creatinine, µmol/l, median (range) | 73.5 (55–153) |
| Total bilirubin, µmol/l, median (range) | 18 (4–88) |
| Albumin, g/l, median (range) | 33 (22–42) |
| MELD scorea, median (range) | 7.5 (4–16) |
| Patients with MELD scores ≥10, n | 14 |
| Serum alpha-fetoprotein level, median (range) | 123 (1–206 006) |
| Patients with serum AFP ≥100 ng/ml, n | 24 |
a
MELD scores at diagnosis were calculated without adjusting for extra points for the presence of hepatocellular carcinoma.36
TNM, tumour–node–metastasis; AJCC, American Joint Committee on Cancer; MELD, Model for End-stage Liver Disease; AFP, alpha-fetoprotein.